HOPA Annual Conference - Hematology/Oncology Pharmacy Association Annual Conference

21-gene profiling is also preferred for patients with 1 to 3 pathologically positive lymph nodes, according to a presentation at the Hematology/Oncology Pharmacy Association conference.

Christy S. Harris, PharmD, BCOP, FHOPA, clinical pharmacy specialist at Dana-Farber Cancer Institute, discusses guidelines for common therapies and appropriate monitoring recommendations for selected therapies used in the treatment of adult sarcomas.

Heidi D. Finnes, PharmD, BCOP, FHOPA, president-elect of Hematology/Oncology Pharmacy Association (HOPA), discusses ways to address burnout in the hematology/oncology space.

Heidi D. Finnes, PharmD, BCOP, FHOPA, president-elect of Hematology/Oncology Pharmacy Association (HOPA), provides details of the upcoming HOPA 2022 conference.

Heidi D. Finnes, PharmD, BCOP, FHOPA, president-elect of Hematology/Oncology Pharmacy Association (HOPA), provides details of the upcoming HOPA 2022 conference.

Larry Buie, PharmD, BCOP, FASHP, outgoing president of the Hematology/Oncology Pharmacy Association (HOPA), shares some details of HOPA’s upcoming 2022 annual conference in Boston and provides an overview of his term as HOPA’s president.

Pharmacy Times will be covering the upcoming Hematology and Oncology Pharmacy Association (HOPA) Association Annual Conference live in Boston, Massachusetts, taking place March 30 through April 2.

Among somatic mutations, approximately 89% of patients with metastatic castration-resistant prostate cancer have a potentially actionable mutation.

Hematology/Oncology Pharmacy Association plans to develop tools and resources to support those conducting research in the oncology pharmacy field, with the goal of promoting pharmacist-led research and improving the ability to analyze difficult scientific questions.

Patient interactions became vastly different during the pandemic, with questions surrounding how to coordinate contact and how to best provide pharmacy services virtually, including counseling, fielding drug information questions, medication reconciliation, and providing home medication sheets to families

Olaparib and niraparib both show promise in the maintenance treatment of ovarian cancer, though they may each be appropriate for different patient populations.

Pharmacokinetic differences in pediatric patients should be considered when administering direct oral anticoagulants, as should potential administration difficulties when pellets or oral solutions are not available.

Selection of any BTK inhibitors for mantle cell lymphoma should consider factors such as cardiovascular or bleeding risks, predisposition for gastrointestinal adverse effects, and potential medication nonadherence.

CLL is the most common leukemia in adult patients in the western world, with 21,040 estimated new cases in 2020.

For unresectable gastrointestinal stromal tumors, the introduction of imatinib revolutionized treatment.

Urothelial carcinoma is the sixth most common cancer diagnosis in the United States, with an estimated 81,400 new diagnoses in 2020 and 17,980 deaths.

Oral chemotherapies can be effective treatments for children with low-grade gliomas, although clinicians should consider available formulations and administration schedules.

Home infusion within the larger ambulatory infusion setting poses some specific advantages and disadvantages in relation to the other location options available.

In each trial, overall response rate and median progression-free survival in the novel treatment arm showed significant improvement over the sunitinib treatment arm in patients with renal cell carcinoma.

Lakesha M. Butler, PharmD, BCPS, diversity and inclusion coordinator and clinical professor at Southern Illinois University Edwardsville, discussed causes of health inequity and how pharmacists can prevent and mitigate them to improve patient outcomes.

A drug recycling program can help increase patient access and minimize waste of expensive oral cancer medications.

Promising investigational oncology drugs include oral taxanes, small molecule drugs, and immunotherapies.

Common factors that contributed to reported increased dissatisfaction at work include role conflict, quantity of work, workflow disruptions, organizational culture, and leadership support.

Even while therapeutically anticoagulated, patients with cancer have risk factors for recurring venous thromboembolism and bleeding, according to a session at the Hematology/Oncology Pharmacy Association 2021 Virtual Annual Conference.

A session at the Hematology/Oncology Pharmacy Association Virtual Annual Conference provided an overview of how treatment options are changing with potential new therapies in development for patients with non-small cell lung cancer.

Over the past 18 months, the FDA has approved 4 new regimens for HER2-positive metastatic disease.

Although many attendees and presenters are looking forward to returning to in-person conferences in the future, Anne Krolikowski said the virtual format of their upcoming conference allows even more people to attend.

As hematology and oncology pharmacists have become increasingly essential members of the care team, new investigational drugs could have a significant impact on the treatment landscape.

Understanding the role of abemaciclib (Verzenio) in managing patients with hormone receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer is crucial.

Amid rising cancer care costs, a focus on chemotherapy stewardship may result in cost savings, according to a session of the HOPA Practice Management 2020 Virtual Learning Event.